Biocon Biologics CEO On Interchangeability Dynamics For Humira Biosimilar
Ustekinumab, Denosumab And Pertuzumab Biosimilars Progress
Biocon Biologics’ CEO indicates that interchangeability may not be pivotal to commercial success in the US for biosimilar adalimumab and that the firm’s Humira rival “checks the key boxes.”
You may also be interested in...
EirGenix Looks For Partner As Pertuzumab Passes Phase I
With EirGenix about to start Phase III trials for its proposed biosimilar version of Perjeta, the Taiwanese developer says it is negotiating with global firms for rights to the pertuzumab candidate.
Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.
AbbVie Pinpoints US Humira Erosion At 37% In 2023
With adalimumab biosimilars now on market in the US, AbbVie said it expects sales erosion this year toward the lower end of its previous guidance, with pricing comprising the larger portion of the hit.